publication date: Nov. 29, 2016

Prostate Cancer Axumin Detects 68% of Recurrent Prostate Cancer in Phase III Study

Blue Earth Diagnostics Ltd. announced the peer-reviewed publication of results from a phase III clinical trial of Axumin (fluciclovine F 18) injection.

Axumin is a novel molecular imaging agent indicated for use in positron emission tomography imaging in men with suspected prostate cancer recurrence based on elevated blood levels of prostate specific antigen following prior treatment.

Results of the multi-center study, conducted in Norway, Italy and the United States, demonstrated a 68% overall detection rate for Axumin, with the ability to detect local, as well as distant, prostate cancer recurrence across a wide range of PSA values. Axumin was well tolerated in the study.

The manuscript, “Multi-site experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) PET/CT imaging in the staging of biochemically recurrent prostate cancer,” was accepted by The Journal of Urology and is now available online: J Urol 2016; doi:10.1016/j.juro.2016.09.117. The manuscript will also appear in an upcoming print issue. The lead authors are T. Bach-Gansmo of Oslo University, Oslo, Norway; C. Nanni of the University of Bologna, Bologna, Italy and P.T. Nieh of Emory University.

“Axumin was designed and developed by Dr. Mark Goodman at Emory University to enable visualization with PET imaging of increased amino acid transport that occurs in many cancers,” … Continue reading CCL Nov 2016 – Axumin Detects 68% of Recurrent Prostate Cancer in Phase III Study

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.